CASE DESCRIPTION Five-year-old female patient with hereditary hemorrhagic telangiectasia. CLINICAL FINDINGS Deterioration of cardiopulmonary function with higher oxygen requirements secondary to pulmonary arteriovenous shunts, epistaxis. TREATMENT AND OUTCOME The patient was treated with the monoclonal antibody bevacizumab, which inhibits the vascular endothelial growth factor, with good cl...

Dr. Cates: This man, who was employed as a fireman in an aircraft factory, died from vomiting blood on the 7th December last year. He was a known victim of familial telangiectasia and had had several previous episodes of haemorrhage from the gut which had been very severe. Before he died he developed a fresh disease for which he received a course of nitrogen mustard. In 1930, at the age of 31, ...

BACKGROUND Hereditary hemorrhagic telangiectasia is characterized by angiodysplastic lesions. So far, knowledge is limited on the vascular architecture and rate of occult manifestation of telangiectases. Contact endoscopy has not been used for this task before. METHODS Eleven patients with hereditary hemorrhagic telangiectasia were examined with contact endoscopy to identify occult telangiect...

This is the first scientific report of hereditary hemorrhagic telangiectasia (HHT) epistaxis treatment by intranasal spraying of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). Epistaxis in patients with HHT is a morbid, mortal condition that is difficult and unpleasant to manage. Nasal telangiectasia growth is modulated by VEGF, which is elevated in HHT patients....

Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome is an inherited disorder characterized by vascular dysplasias leading to hemorrhages. If affects approximately 1 in 10,000 Caucasian people. The most common presentation chronic and recurrent epistaxis whereas bleeding from other sites can lead life-threatening complications.